22nd Jul 2021 15:28
(Alliance News) - GlaxoSmithKline PLC on Thursday said Brian McNamara, chief executive of its Consumer Healthcare unit, has been appointed CEO designate of a new, independent company, which will result from the proposed demerger of Consumer Healthcare from GSK in 2022.
GSK Consumer Healthcare was a joint venture between Brentford, London-based pharmaceutical firm GlaxoSmithKline and Brooklyn, New York-based coronavirus jab maker Pfizer Inc.
"I am confident we are well positioned for growth, building on our brands and innovation, with leading-edge science and human understanding, to deliver better everyday health," said McNamara.
McNamara joined GSK in 2015 as head of its over the counter division. He will lead the new firm with a portfolio that generated annual sales over GBP10 billion in 2020. Its portfolio will include consumer healthcare brands Sensodyne, Voltaren, Panadol and Centrum.
Consumer Healthcare is expected to trade on the London Stock Exchange.
By Josie O'Brien; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline